التفاصيل البيبلوغرافية
| العنوان: |
Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies. |
| المؤلفون: |
Nicolas, Philippe, Marion-Moffet, Hugo, Gossez, Morgane, Vukusic, Sandra, Monneret, Guillaume, Marignier, Romain, Venet, Fabienne |
| المصدر: |
Journal of Neurology; Jan2023, Vol. 270 Issue 1, p32-36, 5p |
| مصطلحات موضوعية: |
HUMORAL immunity, CD19 antigen, MONOCLONAL antibodies, MULTIPLE sclerosis, NEUROMYELITIS optica |
| مستخلص: |
We tested 61 anti-CD20-treated MS patients (anti-CD20 patients) and 10 healthy volunteers. Dear Sirs, Multiple sclerosis (MS) patients treated with anti-CD20 monoclonal antibodies are at higher risk of severe COVID-19 [[1]]. The repartition of immune response status was significantly different in patients with or without B-cell repletion (B-cell repletion being defined as >= 1 CD20 + B cell/mm SP 3 sp 6 months after previous anti-CD20 infusion) ( I p < i 0.0001) (Fig. [Extracted from the article] |
|
Copyright of Journal of Neurology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
